The dark side of PD-1 receptor inhibition

Aya Ludin and Leonard I. Zon ()
Additional contact information
Aya Ludin: Harvard Stem Cell Institute, Harvard University
Leonard I. Zon: Harvard Stem Cell Institute, Harvard University

Nature, 2017, vol. 552, issue 7683, 41-42

Abstract: Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves. See Letter p.121

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature24759 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:552:y:2017:i:7683:d:10.1038_nature24759

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature24759

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().